This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.Immunity 37(1):1a2 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991a998 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R ... July 2010. http://www.ema.europa.eu/docs/en_GB/ document_library/ Scientific_guideline/2010/09/ WC500096730.pdf FDA (2009) ... Nat Biotechnol 27:129a139 Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation.
|Title||:||Cancer Immunotherapy Meets Oncology|
|Author||:||Cedrik Michael Britten|
|Publisher||:||Springer - 2014-01-01|